Novo Nordisk A/S (NONOF)

OTCMKTS · Delayed Price · Currency is USD
66.93
+1.79 (2.74%)
May 12, 2025, 3:53 PM EDT
-48.02%
Market Cap 292.03B
Revenue (ttm) 43.92B
Net Income (ttm) 15.16B
Shares Out n/a
EPS (ttm) 3.40
PE Ratio 19.27
Forward PE 16.54
Dividend 1.66 (2.48%)
Ex-Dividend Date Mar 28, 2025
Volume 700
Average Volume 197,727
Open 65.99
Previous Close 65.14
Day's Range 64.09 - 67.79
52-Week Range 55.28 - 149.55
Beta 0.21
RSI 51.32
Earnings Date May 7, 2025

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]

Sector Healthcare
Founded 1923
Employees 77,349
Stock Exchange OTCMKTS
Ticker Symbol NONOF
Full Company Profile

Financial Performance

In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.

Financial numbers in DKK Financial Statements

News

50 Fortune World's Most Admired Companies (FWMAC): 24 "Safer", 1 Ideal Buy

Fortune and Korn Ferry's survey identified the top 50 Most Admired Companies, focusing on criteria like investment value, management quality, and social responsibility. Four dividend-paying companies,...

7 hours ago - Seeking Alpha

Trump calls out weight-loss drugs as target of price-cut push

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its push to lower prescription drug prices.

9 hours ago - Reuters

Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know

President Donald Trump wants to lower U.S. drug costs by linking prices to those paid in other developed countries – a move that experts say could face a challenging path to becoming a reality.  Trump...

9 hours ago - CNBC

Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices

Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.

13 hours ago - CNBC Television

Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet

President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t...

13 hours ago - Seeking Alpha

Novo Nordisk's Sogroya Supports Effective Weekly Alternative To Daily Hormone Therapy Across Three Growth Disorders

Novo Nordisk reports phase 3 data ... Full story available on Benzinga.com

16 hours ago - Benzinga

Novo Nordisk Stock Is Slumping Today. Here's Why.

Shares of the Ozempic-maker fell while the rest of the market rose,as it's facing a hit to revenue from different directions.

17 hours ago - Barrons

Eli Lilly’s Zepbound shows superior weight loss over Novo Nordisk's Wegovy in trial

Eli Lilly's Zepbound outshines Wegovy in a Phase 3b trial, delivering superior weight loss results.

18 hours ago - Seeking Alpha

Here’s how much extra weight is lost with Zepbound over Wegovy

A study of two blockbuster weight-loss drugs came out in favor of Eli Lilly over its rival Novo Nordisk.

19 hours ago - MarketWatch

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

Novo Nordisk, which generates around 60% of its sales in the U.S., is among the biggest losers in early European trade.

20 hours ago - WSJ

Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket

On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the “ most consequential executive order ” in U.S. history, aimed at lowering prescription drug prices....

21 hours ago - Benzinga

Eli Lilly's Zepbound Shows Superior Weight Loss Over Novo Nordisk's Wegovy In Head-To-Head Trial

Eli Lilly and Company’s (NYSE: LLY) Zepbound demonstrated superior weight reduction compared to Novo Nordisk A/S’s (NYSE: NVO) Wegovy in a 72-week head-to-head trial. What Happened: Participants tre...

21 hours ago - Benzinga

Pharmaceutical stocks slide as Trump vows to cut US prescription drug prices ‘by 30-80%'

President plans to use executive powers, saying US should pay ‘same price as nation that pays the lowest price'

22 hours ago - The Guardian

Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and well-tolerated long-acting growth hormone in children with growth disorders: results from REAL8 phase 3 basket study presented at the joint Congress of ESPE and ESE

Bagsværd, Denmark, 12 May 2025 – Novo Nordisk today presented data from the phase 3 REAL8 basket study, which showed that once-weekly Sogroya® (somapacitan) was non-inferior to the once-daily growth h...

23 hours ago - GlobeNewsWire

Eli Lilly's (LLY) Zepbound Outperforms Novo Nordisk's Wegovy in Weight Loss Study

Eli Lilly's (LLY) Zepbound Outperforms Novo Nordisk's Wegovy in Weight Loss Study

1 day ago - GuruFocus

Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.

1 day ago - Reuters

Wellness companies eager to avoid WeightWatchers' fate embrace weight-loss drugs

Health and wellness companies are embracing weight-loss drugs and building offerings around them in an effort to avoid the fate of WeightWatchers, which declared bankruptcy this week, citing vastly in...

2 days ago - Reuters

Pharma Worries Shift to Prices From Trade. Trump's Next Plan Could Sink Stocks.

The president says big news about drug pricing is coming next week.

3 days ago - Barrons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 9 May 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons i...

3 days ago - GlobeNewsWire

Currency hedging and new U.S. factories: Novo Nordisk CFO thinks Wegovy maker can outmaneuver global trade wars

Novo Nordisk's CFO says the company is well-placed to respond to an escalation of the global trade war.

3 days ago - Fortune

Pressure is still on the pharma sector, says Mizuho's Jared Holz

Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.

4 days ago - CNBC Television

Hims & Hers Stock's 100% Surge Is Squeezing Shorts And It Might Just Be Getting Started

If short sellers were hoping for a flop from Hims & Hers Health Inc. (NYSE: HIMS), they may want to check their risk management settings. The telehealth disruptor dropped first-quarter earnings after...

4 days ago - Benzinga

Novo Nordisk posts strong Q1 as weight-loss revolution claims another victim: WeightWatchers

One day after WeightWatchers said that it would file for bankruptcy, weight-loss drug giant Novo Nordisk's outlook is brightening.

4 days ago - Fast Company